| Name | Title | Contact Details |
|---|---|---|
Justin Guthrie |
Chief Financial and Strategy Officer | Profile |
Axolight is a lighting company, based in Italy and the United States, which designs and produces high-end decorative design lamps. Handmade in Italy Each Axolight product, whether it derives from mass production or from a customized request, is designed, developed, tested and assembled by hand at the company workshop in Venice - Scorzè.
Coach & Equipment Mfg. Corp is a manufacturer of mid-sized buses serving the paratransit industry. With roots dating back to the 1870s, Coach & Equipment has a long history of manufacturing excellence. We pride ourselves in building safe and reliable buses that are carefully engineered and manufactured at our plant in Penn Yan, New York. In an industry that is becoming increasing consolidated, our company remains family-run and passionate about providing outstanding customer care.
Introducing QXO.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.